
Nuvation Bio’s IBTROZI™ Approved in Japan for Advanced ROS1+ NSCLC
Nuvation Bio Secures Japan Approval for IBTROZI™ in ROS1-Positive Advanced NSCLC, Strengthening Global Expansion of Its Oncology Portfolio Nuvation Bio Inc. (NYSE: NUVB), a global oncology company dedicated to advancing innovative treatments for some of the most challenging cancers, has…












